+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression



CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression



Biological Psychiatry 29(11): 1110-1118



Decreased cerebrospinal fluid (CSF), somatostatinlike immunoreactivity (SLI) and alterations in the CSF monamine metabolites 3-methoxy-4-hydroxyphenylethylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) have been reported in patients with probable Alzheimer's disease (AD) and in patients with major depression. In this study, we found CSF SLI to be significantly lower in a large group of AD patients (n = 60) and in a group of age-matched patients with major depression (n = 18) as compared with normal controls (n = 12). Mean CSF, MHPG, 5-HIAA, and HVA levels were not significantly different among diagnostic groups. Within a group of "depressed" AD patients, CSF levels of 5-HIAA showed a significant positive correlation (p = 0.03) with CSF SLI; a similar relationship was found within the group of patients with major depression. Further exploration of the relationship between the somatostatin and serotonin systems may provide clues as to how neuropeptides interact with monoamine neurotransmitters and what role they have in depression.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039435835

Download citation: RISBibTeXText

PMID: 1714776

DOI: 10.1016/0006-3223(91)90253-i


Related references

CSF somatostatin in Alzheimer's disease and major depression: Relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology 18(7): 509-519, 1993

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 5(3): 193-202, 1993

Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23(12b): 1561-1569, 1984

Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biological Psychiatry. 33(8-9): 636-641, 1993

Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease. British Journal of Psychiatry 124(0): 280-287, 1974

Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging 19(5): 379-384, 1998

Somatostatin in Alzheimer's disease and depression. Life Sciences 51(18): 1389-1410, 1992

Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: A postmortem study. Cellular and Molecular Neurobiology 12(6): 581-587, 1992

Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. Psychopharmacology 91(3): 293-296, 1987

Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer's disease). Acta Psychiatrica Scandinavica 49(3): 257-263, 1973

CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites. Biological Psychiatry 26(5): 500-504, 1989

The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 5(3): 185-192, 1993

Somatostatin: a neuropeptide system pathologically altered in Alzheimer's disease and depression. Clinical Neuropharmacology 15 Suppl 1 Pt A: 311a-312a, 1992

The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines. International Psychogeriatrics 2(2): 99, 1990

Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. Journal of the Neurological Sciences 133(1-2): 73-78, 1995